Octopus Biosafety SA (EPA:MLOCT)
France · Delayed Price · Currency is EUR 0.1390
0.00 (0.00%)
Aug 19, 2026, 11:30 AM CET
Octopus Biosafety Income Statement
Financials in millions EUR. Fiscal year is January - December.
Millions EUR. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Operating Revenue | 0.39 | 0.66 | 0.28 | 0.54 | 0.66 |
Other Revenue | 0 | -0 | 0 | - | 0 |
| 0.39 | 0.66 | 0.28 | 0.54 | 0.66 | |
Revenue Growth | -41.27% | 136.30% | -48.32% | -18.85% | 5013.35% |
Cost of Revenue | 0.72 | 0.73 | 0.33 | 0.48 | 0.86 |
Gross Profit | -0.34 | -0.07 | -0.06 | 0.05 | -0.2 |
Selling, General & Admin | 0.47 | 0.48 | 0.43 | 0.66 | 0.71 |
Other Operating Expenses | -0.65 | -0.01 | -0.01 | 0 | 0.01 |
Operating Expenses | 0.5 | 1.37 | 0.67 | 1.17 | 1.2 |
Operating Income | -0.84 | -1.44 | -0.73 | -1.12 | -1.4 |
Interest Expense | -0 | -0 | -0 | -0.01 | -0.01 |
Currency Exchange Gain (Loss) | - | - | - | 0 | -0 |
Other Non Operating Income (Expenses) | -0 | 0 | -0 | 0 | - |
EBT Excluding Unusual Items | -0.84 | -1.44 | -0.73 | -1.13 | -1.41 |
Gain (Loss) on Sale of Assets | - | 0.03 | 0.07 | -0.08 | -0.03 |
Other Unusual Items | -0.03 | -0.56 | -0.3 | -0.05 | 0.38 |
Pretax Income | -0.87 | -1.97 | -0.96 | -1.26 | -1.06 |
Income Tax Expense | -0.21 | -0.19 | -0.16 | -0.25 | -0.23 |
Net Income | -0.66 | -1.78 | -0.8 | -1.01 | -0.83 |
Net Income to Common | -0.66 | -1.78 | -0.8 | -1.01 | -0.83 |
Net Income Growth | - | - | - | - | - |
Shares Outstanding (Basic) | 15 | 15 | 4 | 4 | 4 |
Shares Outstanding (Diluted) | 15 | 15 | 4 | 4 | 4 |
Shares Change | 1.32% | 264.33% | - | - | - |
EPS (Basic) | -0.04 | -0.12 | -0.20 | -0.25 | -0.21 |
EPS (Diluted) | -0.04 | -0.12 | -0.20 | -0.25 | -0.21 |
EPS Growth | - | - | - | - | - |
Additional Metrics
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Gross Margin | -87.32% | -10.67% | -19.87% | 10.21% | -30.05% |
Operating Margin | -217.46% | -219.33% | -261.62% | -208.59% | -211.76% |
Profit Margin | -171.15% | -271.02% | -289.29% | -188.21% | -125.74% |
EBITDA | -0.15 | -0.54 | -0.48 | -0.61 | -0.92 |
EBITDA Margin | -40.18% | -82.20% | -171.90% | -113.38% | -139.66% |
D&A For EBITDA | 0.68 | 0.9 | 0.25 | 0.51 | 0.48 |
EBIT | -0.84 | -1.44 | -0.73 | -1.12 | -1.4 |
EBIT Margin | -217.46% | -219.33% | -261.62% | -208.59% | -211.76% |
Revenue as Reported | 0.97 | 0.6 | 0.4 | 0.58 | 0.65 |